Tumours with PTEN loss showed inferior reduction in tumour size versus those with retained expression after treatment with nivolumab or pembrolizumab, while a combination PI3Kβ inhibition and anti-PD1 therapy in mouse models of PTEN null melanoma achieved improved tumour control versus either agent alone [62]. The gene discussed is PTEN; the disease is neoplasm.